

Global HIV Antiretroviral Drug Market Research Report 2023

https://marketpublishers.com/r/G31180CEC21FEN.html

Date: October 2023

Pages: 147

Price: US\$ 2,900.00 (Single User License)

ID: G31180CEC21FEN

Abstracts

This report aims to provide a comprehensive presentation of the global market for HIV Antiretroviral Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding HIV Antiretroviral Drug.

The HIV Antiretroviral Drug market size, estimations, and forecasts are provided in terms of and revenue (\$ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global HIV Antiretroviral Drug market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the HIV Antiretroviral Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

By Company

ViiV Healthcare(GlaxoSmithKline)

Gilead Sciences



AbbVie Inc.	
Merck & Co	
GSK	
Bristol-Myers Squibb Company	
Theratechnologies Inc.	
Roche Holding AG	
Teva Pharmaceuticals	
Pfizer	
Frontier Biotechnologies	
Shionogi	
Julphar Bangladesh	
Mylan Pharmaceuticals Inc.	
Genentech, Inc.	
Boehringer Ingelheim	
Cipla	
MSD	
Abbott	
Johnson & Johnson	
Biocon Limited	



Affine Formulations Limited	
IPCA Laboratories	
Natco Pharma	
Beacon Pharmaceuticals	
Segment by Type	
Nucleoside Reverse Transcr	iptase Inhibitors
Non-Nucleoside Reverse Tra	anscriptase Inhibitors
Protease Inhibitors	
Fusion Inhibitors	
Others	
Segment by Application	
Hospital Pharmacies	
Retail Pharmacies	
Online Pharmacies	
By Region	
North America	
United States	
Canada	



Europe Germany France UK Italy Russia **Nordic Countries** Rest of Europe Asia-Pacific China Japan South Korea Southeast Asia India Australia Rest of Asia Latin America Mexico Brazil Rest of Latin America



Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of HIV Antiretroviral Drug companies' competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and



development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 12: The main points and conclusions of the report.



Contents

1 REPORT OVERVIEW

- 1.1 Study Scope
- 1.2 Market Analysis by Type
- 1.2.1 Global HIV Antiretroviral Drug Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
 - 1.2.2 Nucleoside Reverse Transcriptase Inhibitors
 - 1.2.3 Non-Nucleoside Reverse Transcriptase Inhibitors
 - 1.2.4 Protease Inhibitors
 - 1.2.5 Fusion Inhibitors
 - 1.2.6 Others
- 1.3 Market by Application
- 1.3.1 Global HIV Antiretroviral Drug Market Growth by Application: 2018 VS 2022 VS 2029
 - 1.3.2 Hospital Pharmacies
 - 1.3.3 Retail Pharmacies
 - 1.3.4 Online Pharmacies
- 1.4 Study Objectives
- 1.5 Years Considered
- 1.6 Years Considered

2 GLOBAL GROWTH TRENDS

- 2.1 Global HIV Antiretroviral Drug Market Perspective (2018-2029)
- 2.2 HIV Antiretroviral Drug Growth Trends by Region
 - 2.2.1 Global HIV Antiretroviral Drug Market Size by Region: 2018 VS 2022 VS 2029
 - 2.2.2 HIV Antiretroviral Drug Historic Market Size by Region (2018-2023)
 - 2.2.3 HIV Antiretroviral Drug Forecasted Market Size by Region (2024-2029)
- 2.3 HIV Antiretroviral Drug Market Dynamics
 - 2.3.1 HIV Antiretroviral Drug Industry Trends
 - 2.3.2 HIV Antiretroviral Drug Market Drivers
 - 2.3.3 HIV Antiretroviral Drug Market Challenges
 - 2.3.4 HIV Antiretroviral Drug Market Restraints

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top HIV Antiretroviral Drug Players by Revenue



- 3.1.1 Global Top HIV Antiretroviral Drug Players by Revenue (2018-2023)
- 3.1.2 Global HIV Antiretroviral Drug Revenue Market Share by Players (2018-2023)
- 3.2 Global HIV Antiretroviral Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.3 Players Covered: Ranking by HIV Antiretroviral Drug Revenue
- 3.4 Global HIV Antiretroviral Drug Market Concentration Ratio
- 3.4.1 Global HIV Antiretroviral Drug Market Concentration Ratio (CR5 and HHI)
- 3.4.2 Global Top 10 and Top 5 Companies by HIV Antiretroviral Drug Revenue in 2022
- 3.5 HIV Antiretroviral Drug Key Players Head office and Area Served
- 3.6 Key Players HIV Antiretroviral Drug Product Solution and Service
- 3.7 Date of Enter into HIV Antiretroviral Drug Market
- 3.8 Mergers & Acquisitions, Expansion Plans

4 HIV ANTIRETROVIRAL DRUG BREAKDOWN DATA BY TYPE

- 4.1 Global HIV Antiretroviral Drug Historic Market Size by Type (2018-2023)
- 4.2 Global HIV Antiretroviral Drug Forecasted Market Size by Type (2024-2029)

5 HIV ANTIRETROVIRAL DRUG BREAKDOWN DATA BY APPLICATION

- 5.1 Global HIV Antiretroviral Drug Historic Market Size by Application (2018-2023)
- 5.2 Global HIV Antiretroviral Drug Forecasted Market Size by Application (2024-2029)

6 NORTH AMERICA

- 6.1 North America HIV Antiretroviral Drug Market Size (2018-2029)
- 6.2 North America HIV Antiretroviral Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 6.3 North America HIV Antiretroviral Drug Market Size by Country (2018-2023)
- 6.4 North America HIV Antiretroviral Drug Market Size by Country (2024-2029)
- 6.5 United States
- 6.6 Canada

7 EUROPE

- 7.1 Europe HIV Antiretroviral Drug Market Size (2018-2029)
- 7.2 Europe HIV Antiretroviral Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 7.3 Europe HIV Antiretroviral Drug Market Size by Country (2018-2023)



- 7.4 Europe HIV Antiretroviral Drug Market Size by Country (2024-2029)
- 7.5 Germany
- 7.6 France
- 7.7 U.K.
- 7.8 Italy
- 7.9 Russia
- 7.10 Nordic Countries

8 ASIA-PACIFIC

- 8.1 Asia-Pacific HIV Antiretroviral Drug Market Size (2018-2029)
- 8.2 Asia-Pacific HIV Antiretroviral Drug Market Growth Rate by Region: 2018 VS 2022
- VS 2029
- 8.3 Asia-Pacific HIV Antiretroviral Drug Market Size by Region (2018-2023)
- 8.4 Asia-Pacific HIV Antiretroviral Drug Market Size by Region (2024-2029)
- 8.5 China
- 8.6 Japan
- 8.7 South Korea
- 8.8 Southeast Asia
- 8.9 India
- 8.10 Australia

9 LATIN AMERICA

- 9.1 Latin America HIV Antiretroviral Drug Market Size (2018-2029)
- 9.2 Latin America HIV Antiretroviral Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 9.3 Latin America HIV Antiretroviral Drug Market Size by Country (2018-2023)
- 9.4 Latin America HIV Antiretroviral Drug Market Size by Country (2024-2029)
- 9.5 Mexico
- 9.6 Brazil

10 MIDDLE EAST & AFRICA

- 10.1 Middle East & Africa HIV Antiretroviral Drug Market Size (2018-2029)
- 10.2 Middle East & Africa HIV Antiretroviral Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 10.3 Middle East & Africa HIV Antiretroviral Drug Market Size by Country (2018-2023)
- 10.4 Middle East & Africa HIV Antiretroviral Drug Market Size by Country (2024-2029)



- 10.5 Turkey
- 10.6 Saudi Arabia
- 10.7 UAE

11 KEY PLAYERS PROFILES

- 11.1 ViiV Healthcare(GlaxoSmithKline)
 - 11.1.1 ViiV Healthcare(GlaxoSmithKline) Company Detail
 - 11.1.2 ViiV Healthcare(GlaxoSmithKline) Business Overview
 - 11.1.3 ViiV Healthcare(GlaxoSmithKline) HIV Antiretroviral Drug Introduction
- 11.1.4 ViiV Healthcare(GlaxoSmithKline) Revenue in HIV Antiretroviral Drug Business (2018-2023)
 - 11.1.5 ViiV Healthcare(GlaxoSmithKline) Recent Development
- 11.2 Gilead Sciences
 - 11.2.1 Gilead Sciences Company Detail
 - 11.2.2 Gilead Sciences Business Overview
 - 11.2.3 Gilead Sciences HIV Antiretroviral Drug Introduction
 - 11.2.4 Gilead Sciences Revenue in HIV Antiretroviral Drug Business (2018-2023)
 - 11.2.5 Gilead Sciences Recent Development
- 11.3 AbbVie Inc.
 - 11.3.1 AbbVie Inc. Company Detail
 - 11.3.2 AbbVie Inc. Business Overview
 - 11.3.3 AbbVie Inc. HIV Antiretroviral Drug Introduction
- 11.3.4 AbbVie Inc. Revenue in HIV Antiretroviral Drug Business (2018-2023)
- 11.3.5 AbbVie Inc. Recent Development
- 11.4 Merck & Co
 - 11.4.1 Merck & Co Company Detail
 - 11.4.2 Merck & Co Business Overview
 - 11.4.3 Merck & Co HIV Antiretroviral Drug Introduction
 - 11.4.4 Merck & Co Revenue in HIV Antiretroviral Drug Business (2018-2023)
 - 11.4.5 Merck & Co Recent Development
- 11.5 GSK
 - 11.5.1 GSK Company Detail
 - 11.5.2 GSK Business Overview
 - 11.5.3 GSK HIV Antiretroviral Drug Introduction
 - 11.5.4 GSK Revenue in HIV Antiretroviral Drug Business (2018-2023)
 - 11.5.5 GSK Recent Development
- 11.6 Bristol-Myers Squibb Company
 - 11.6.1 Bristol-Myers Squibb Company Company Detail



- 11.6.2 Bristol-Myers Squibb Company Business Overview
- 11.6.3 Bristol-Myers Squibb Company HIV Antiretroviral Drug Introduction
- 11.6.4 Bristol-Myers Squibb Company Revenue in HIV Antiretroviral Drug Business (2018-2023)
 - 11.6.5 Bristol-Myers Squibb Company Recent Development
- 11.7 Theratechnologies Inc.
 - 11.7.1 Theratechnologies Inc. Company Detail
 - 11.7.2 Theratechnologies Inc. Business Overview
 - 11.7.3 Theratechnologies Inc. HIV Antiretroviral Drug Introduction
- 11.7.4 Theratechnologies Inc. Revenue in HIV Antiretroviral Drug Business (2018-2023)
 - 11.7.5 Theratechnologies Inc. Recent Development
- 11.8 Roche Holding AG
 - 11.8.1 Roche Holding AG Company Detail
 - 11.8.2 Roche Holding AG Business Overview
 - 11.8.3 Roche Holding AG HIV Antiretroviral Drug Introduction
 - 11.8.4 Roche Holding AG Revenue in HIV Antiretroviral Drug Business (2018-2023)
 - 11.8.5 Roche Holding AG Recent Development
- 11.9 Teva Pharmaceuticals
 - 11.9.1 Teva Pharmaceuticals Company Detail
- 11.9.2 Teva Pharmaceuticals Business Overview
- 11.9.3 Teva Pharmaceuticals HIV Antiretroviral Drug Introduction
- 11.9.4 Teva Pharmaceuticals Revenue in HIV Antiretroviral Drug Business (2018-2023)
 - 11.9.5 Teva Pharmaceuticals Recent Development
- 11.10 Pfizer
 - 11.10.1 Pfizer Company Detail
 - 11.10.2 Pfizer Business Overview
 - 11.10.3 Pfizer HIV Antiretroviral Drug Introduction
 - 11.10.4 Pfizer Revenue in HIV Antiretroviral Drug Business (2018-2023)
 - 11.10.5 Pfizer Recent Development
- 11.11 Frontier Biotechnologies
 - 11.11.1 Frontier Biotechnologies Company Detail
 - 11.11.2 Frontier Biotechnologies Business Overview
 - 11.11.3 Frontier Biotechnologies HIV Antiretroviral Drug Introduction
- 11.11.4 Frontier Biotechnologies Revenue in HIV Antiretroviral Drug Business (2018-2023)
 - 11.11.5 Frontier Biotechnologies Recent Development
- 11.12 Shionogi



- 11.12.1 Shionogi Company Detail
- 11.12.2 Shionogi Business Overview
- 11.12.3 Shionogi HIV Antiretroviral Drug Introduction
- 11.12.4 Shionogi Revenue in HIV Antiretroviral Drug Business (2018-2023)
- 11.12.5 Shionogi Recent Development
- 11.13 Julphar Bangladesh
 - 11.13.1 Julphar Bangladesh Company Detail
 - 11.13.2 Julphar Bangladesh Business Overview
 - 11.13.3 Julphar Bangladesh HIV Antiretroviral Drug Introduction
 - 11.13.4 Julphar Bangladesh Revenue in HIV Antiretroviral Drug Business (2018-2023)
- 11.13.5 Julphar Bangladesh Recent Development
- 11.14 Mylan Pharmaceuticals Inc.
- 11.14.1 Mylan Pharmaceuticals Inc. Company Detail
- 11.14.2 Mylan Pharmaceuticals Inc. Business Overview
- 11.14.3 Mylan Pharmaceuticals Inc. HIV Antiretroviral Drug Introduction
- 11.14.4 Mylan Pharmaceuticals Inc. Revenue in HIV Antiretroviral Drug Business (2018-2023)
 - 11.14.5 Mylan Pharmaceuticals Inc. Recent Development
- 11.15 Genentech, Inc.
 - 11.15.1 Genentech, Inc. Company Detail
 - 11.15.2 Genentech, Inc. Business Overview
 - 11.15.3 Genentech, Inc. HIV Antiretroviral Drug Introduction
 - 11.15.4 Genentech, Inc. Revenue in HIV Antiretroviral Drug Business (2018-2023)
- 11.15.5 Genentech, Inc. Recent Development
- 11.16 Boehringer Ingelheim
 - 11.16.1 Boehringer Ingelheim Company Detail
 - 11.16.2 Boehringer Ingelheim Business Overview
- 11.16.3 Boehringer Ingelheim HIV Antiretroviral Drug Introduction
- 11.16.4 Boehringer Ingelheim Revenue in HIV Antiretroviral Drug Business (2018-2023)
- 11.16.5 Boehringer Ingelheim Recent Development
- 11.17 Cipla
 - 11.17.1 Cipla Company Detail
 - 11.17.2 Cipla Business Overview
 - 11.17.3 Cipla HIV Antiretroviral Drug Introduction
 - 11.17.4 Cipla Revenue in HIV Antiretroviral Drug Business (2018-2023)
 - 11.17.5 Cipla Recent Development
- 11.18 MSD
- 11.18.1 MSD Company Detail



- 11.18.2 MSD Business Overview
- 11.18.3 MSD HIV Antiretroviral Drug Introduction
- 11.18.4 MSD Revenue in HIV Antiretroviral Drug Business (2018-2023)
- 11.18.5 MSD Recent Development
- 11.19 Abbott
 - 11.19.1 Abbott Company Detail
 - 11.19.2 Abbott Business Overview
 - 11.19.3 Abbott HIV Antiretroviral Drug Introduction
 - 11.19.4 Abbott Revenue in HIV Antiretroviral Drug Business (2018-2023)
 - 11.19.5 Abbott Recent Development
- 11.20 Johnson & Johnson
 - 11.20.1 Johnson & Johnson Company Detail
- 11.20.2 Johnson & Johnson Business Overview
- 11.20.3 Johnson & Johnson HIV Antiretroviral Drug Introduction
- 11.20.4 Johnson & Johnson Revenue in HIV Antiretroviral Drug Business (2018-2023)
- 11.20.5 Johnson & Johnson Recent Development
- 11.21 Biocon Limited
 - 11.21.1 Biocon Limited Company Detail
 - 11.21.2 Biocon Limited Business Overview
 - 11.21.3 Biocon Limited HIV Antiretroviral Drug Introduction
 - 11.21.4 Biocon Limited Revenue in HIV Antiretroviral Drug Business (2018-2023)
 - 11.21.5 Biocon Limited Recent Development
- 11.22 Affine Formulations Limited
 - 11.22.1 Affine Formulations Limited Company Detail
 - 11.22.2 Affine Formulations Limited Business Overview
 - 11.22.3 Affine Formulations Limited HIV Antiretroviral Drug Introduction
- 11.22.4 Affine Formulations Limited Revenue in HIV Antiretroviral Drug Business (2018-2023)
 - 11.22.5 Affine Formulations Limited Recent Development
- 11.23 IPCA Laboratories
 - 11.23.1 IPCA Laboratories Company Detail
 - 11.23.2 IPCA Laboratories Business Overview
 - 11.23.3 IPCA Laboratories HIV Antiretroviral Drug Introduction
 - 11.23.4 IPCA Laboratories Revenue in HIV Antiretroviral Drug Business (2018-2023)
 - 11.23.5 IPCA Laboratories Recent Development
- 11.24 Natco Pharma
 - 11.24.1 Natco Pharma Company Detail
 - 11.24.2 Natco Pharma Business Overview
 - 11.24.3 Natco Pharma HIV Antiretroviral Drug Introduction



- 11.24.4 Natco Pharma Revenue in HIV Antiretroviral Drug Business (2018-2023)
- 11.24.5 Natco Pharma Recent Development
- 11.25 Beacon Pharmaceuticals
 - 11.25.1 Beacon Pharmaceuticals Company Detail
 - 11.25.2 Beacon Pharmaceuticals Business Overview
 - 11.25.3 Beacon Pharmaceuticals HIV Antiretroviral Drug Introduction
- 11.25.4 Beacon Pharmaceuticals Revenue in HIV Antiretroviral Drug Business (2018-2023)
 - 11.25.5 Beacon Pharmaceuticals Recent Development

12 ANALYST'S VIEWPOINTS/CONCLUSIONS

13 APPENDIX

- 13.1 Research Methodology
 - 13.1.1 Methodology/Research Approach
 - 13.1.2 Data Source
- 13.2 Disclaimer
- 13.3 Author Details



List Of Tables

LIST OF TABLES

Table 1. Global HIV Antiretroviral Drug Market Size Growth Rate by Type (US\$ Million):

2018 VS 2022 VS 2029

Table 2. Key Players of Nucleoside Reverse Transcriptase Inhibitors

Table 3. Key Players of Non-Nucleoside Reverse Transcriptase Inhibitors

Table 4. Key Players of Protease Inhibitors

Table 5. Key Players of Fusion Inhibitors

Table 6. Key Players of Others

Table 7. Global HIV Antiretroviral Drug Market Size Growth by Application (US\$ Million):

2018 VS 2022 VS 2029

Table 8. Global HIV Antiretroviral Drug Market Size by Region (US\$ Million): 2018 VS

2022 VS 2029

Table 9. Global HIV Antiretroviral Drug Market Size by Region (2018-2023) & (US\$

Million)

Table 10. Global HIV Antiretroviral Drug Market Share by Region (2018-2023)

Table 11. Global HIV Antiretroviral Drug Forecasted Market Size by Region (2024-2029)

& (US\$ Million)

Table 12. Global HIV Antiretroviral Drug Market Share by Region (2024-2029)

Table 13. HIV Antiretroviral Drug Market Trends

Table 14. HIV Antiretroviral Drug Market Drivers

Table 15. HIV Antiretroviral Drug Market Challenges

Table 16. HIV Antiretroviral Drug Market Restraints

Table 17. Global HIV Antiretroviral Drug Revenue by Players (2018-2023) & (US\$

Million)

Table 18. Global HIV Antiretroviral Drug Market Share by Players (2018-2023)

Table 19. Global Top HIV Antiretroviral Drug Players by Company Type (Tier 1, Tier 2,

and Tier 3) & (based on the Revenue in HIV Antiretroviral Drug as of 2022)

Table 20. Ranking of Global Top HIV Antiretroviral Drug Companies by Revenue (US\$

Million) in 2022

Table 21. Global 5 Largest Players Market Share by HIV Antiretroviral Drug Revenue

(CR5 and HHI) & (2018-2023)

Table 22. Key Players Headquarters and Area Served

Table 23. Key Players HIV Antiretroviral Drug Product Solution and Service

Table 24. Date of Enter into HIV Antiretroviral Drug Market

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global HIV Antiretroviral Drug Market Size by Type (2018-2023) & (US\$



Million)

- Table 27. Global HIV Antiretroviral Drug Revenue Market Share by Type (2018-2023)
- Table 28. Global HIV Antiretroviral Drug Forecasted Market Size by Type (2024-2029) & (US\$ Million)
- Table 29. Global HIV Antiretroviral Drug Revenue Market Share by Type (2024-2029)
- Table 30. Global HIV Antiretroviral Drug Market Size by Application (2018-2023) & (US\$ Million)
- Table 31. Global HIV Antiretroviral Drug Revenue Market Share by Application (2018-2023)
- Table 32. Global HIV Antiretroviral Drug Forecasted Market Size by Application (2024-2029) & (US\$ Million)
- Table 33. Global HIV Antiretroviral Drug Revenue Market Share by Application (2024-2029)
- Table 34. North America HIV Antiretroviral Drug Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029
- Table 35. North America HIV Antiretroviral Drug Market Size by Country (2018-2023) & (US\$ Million)
- Table 36. North America HIV Antiretroviral Drug Market Size by Country (2024-2029) & (US\$ Million)
- Table 37. Europe HIV Antiretroviral Drug Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029
- Table 38. Europe HIV Antiretroviral Drug Market Size by Country (2018-2023) & (US\$ Million)
- Table 39. Europe HIV Antiretroviral Drug Market Size by Country (2024-2029) & (US\$ Million)
- Table 40. Asia-Pacific HIV Antiretroviral Drug Market Size Growth Rate by Region (US\$ Million): 2018 VS 2022 VS 2029
- Table 41. Asia-Pacific HIV Antiretroviral Drug Market Size by Region (2018-2023) & (US\$ Million)
- Table 42. Asia-Pacific HIV Antiretroviral Drug Market Size by Region (2024-2029) & (US\$ Million)
- Table 43. Latin America HIV Antiretroviral Drug Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029
- Table 44. Latin America HIV Antiretroviral Drug Market Size by Country (2018-2023) & (US\$ Million)
- Table 45. Latin America HIV Antiretroviral Drug Market Size by Country (2024-2029) & (US\$ Million)
- Table 46. Middle East & Africa HIV Antiretroviral Drug Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029



Table 47. Middle East & Africa HIV Antiretroviral Drug Market Size by Country (2018-2023) & (US\$ Million)

Table 48. Middle East & Africa HIV Antiretroviral Drug Market Size by Country (2024-2029) & (US\$ Million)

Table 49. ViiV Healthcare(GlaxoSmithKline) Company Detail

Table 50. ViiV Healthcare(GlaxoSmithKline) Business Overview

Table 51. ViiV Healthcare(GlaxoSmithKline) HIV Antiretroviral Drug Product

Table 52. ViiV Healthcare(GlaxoSmithKline) Revenue in HIV Antiretroviral Drug

Business (2018-2023) & (US\$ Million)

Table 53. ViiV Healthcare(GlaxoSmithKline) Recent Development

Table 54. Gilead Sciences Company Detail

Table 55. Gilead Sciences Business Overview

Table 56. Gilead Sciences HIV Antiretroviral Drug Product

Table 57. Gilead Sciences Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US\$ Million)

Table 58. Gilead Sciences Recent Development

Table 59. AbbVie Inc. Company Detail

Table 60. AbbVie Inc. Business Overview

Table 61. AbbVie Inc. HIV Antiretroviral Drug Product

Table 62. AbbVie Inc. Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US\$ Million)

Table 63. AbbVie Inc. Recent Development

Table 64. Merck & Co Company Detail

Table 65. Merck & Co Business Overview

Table 66. Merck & Co HIV Antiretroviral Drug Product

Table 67. Merck & Co Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US\$ Million)

Table 68. Merck & Co Recent Development

Table 69. GSK Company Detail

Table 70. GSK Business Overview

Table 71. GSK HIV Antiretroviral Drug Product

Table 72. GSK Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US\$ Million)

Table 73. GSK Recent Development

Table 74. Bristol-Myers Squibb Company Company Detail

Table 75. Bristol-Myers Squibb Company Business Overview

Table 76. Bristol-Myers Squibb Company HIV Antiretroviral Drug Product

Table 77. Bristol-Myers Squibb Company Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US\$ Million)



- Table 78. Bristol-Myers Squibb Company Recent Development
- Table 79. Theratechnologies Inc. Company Detail
- Table 80. Theratechnologies Inc. Business Overview
- Table 81. Theratechnologies Inc. HIV Antiretroviral Drug Product
- Table 82. Theratechnologies Inc. Revenue in HIV Antiretroviral Drug Business
- (2018-2023) & (US\$ Million)
- Table 83. Theratechnologies Inc. Recent Development
- Table 84. Roche Holding AG Company Detail
- Table 85. Roche Holding AG Business Overview
- Table 86. Roche Holding AG HIV Antiretroviral Drug Product
- Table 87. Roche Holding AG Revenue in HIV Antiretroviral Drug Business (2018-2023)
- & (US\$ Million)
- Table 88. Roche Holding AG Recent Development
- Table 89. Teva Pharmaceuticals Company Detail
- Table 90. Teva Pharmaceuticals Business Overview
- Table 91. Teva Pharmaceuticals HIV Antiretroviral Drug Product
- Table 92. Teva Pharmaceuticals Revenue in HIV Antiretroviral Drug Business
- (2018-2023) & (US\$ Million)
- Table 93. Teva Pharmaceuticals Recent Development
- Table 94. Pfizer Company Detail
- Table 95. Pfizer Business Overview
- Table 96. Pfizer HIV Antiretroviral Drug Product
- Table 97. Pfizer Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US\$ Million)
- Table 98. Pfizer Recent Development
- Table 99. Frontier Biotechnologies Company Detail
- Table 100. Frontier Biotechnologies Business Overview
- Table 101. Frontier Biotechnologies HIV Antiretroviral Drug Product
- Table 102. Frontier Biotechnologies Revenue in HIV Antiretroviral Drug Business
- (2018-2023) & (US\$ Million)
- Table 103. Frontier Biotechnologies Recent Development
- Table 104. Shionogi Company Detail
- Table 105. Shionogi Business Overview
- Table 106. Shionogi HIV Antiretroviral Drug Product
- Table 107. Shionogi Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US\$ Million)
- Table 108. Shionogi Recent Development
- Table 109. Julphar Bangladesh Company Detail
- Table 110. Julphar Bangladesh Business Overview



Table 111. Julphar Bangladesh HIV Antiretroviral Drug Product

Table 112. Julphar Bangladesh Revenue in HIV Antiretroviral Drug Business

(2018-2023) & (US\$ Million)

Table 113. Julphar Bangladesh Recent Development

Table 114. Mylan Pharmaceuticals Inc. Company Detail

Table 115. Mylan Pharmaceuticals Inc. Business Overview

Table 116. Mylan Pharmaceuticals Inc. HIV Antiretroviral Drug Product

Table 117. Mylan Pharmaceuticals Inc. Revenue in HIV Antiretroviral Drug Business

(2018-2023) & (US\$ Million)

Table 118. Mylan Pharmaceuticals Inc. Recent Development

Table 119. Genentech, Inc. Company Detail

Table 120. Genentech, Inc. Business Overview

Table 121. Genentech, Inc. HIV Antiretroviral Drug Product

Table 122. Genentech, Inc. Revenue in HIV Antiretroviral Drug Business (2018-2023) &

(US\$ Million)

Table 123. Genentech, Inc. Recent Development

Table 124. Boehringer Ingelheim Company Detail

Table 125. Boehringer Ingelheim Business Overview

Table 126. Boehringer Ingelheim HIV Antiretroviral Drug Product

Table 127. Boehringer Ingelheim Revenue in HIV Antiretroviral Drug Business

(2018-2023) & (US\$ Million)

Table 128. Boehringer Ingelheim Recent Development

Table 129. Cipla Company Detail

Table 130. Cipla Business Overview

Table 131. Cipla HIV Antiretroviral Drug Product

Table 132. Cipla Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US\$

Million)

Table 133. Cipla Recent Development

Table 134. MSD Company Detail

Table 135. MSD Business Overview

Table 136. MSD HIV Antiretroviral Drug Product

Table 137. MSD Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US\$

Million)

Table 138. MSD Recent Development

Table 139. Abbott Company Detail

Table 140. Abbott Business Overview

Table 141. Abbott HIV Antiretroviral Drug Product

Table 142. Abbott Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US\$

Million)



- Table 143. Abbott Recent Development
- Table 144. Johnson & Johnson Company Detail
- Table 145. Johnson & Johnson Business Overview
- Table 146. Johnson & Johnson HIV Antiretroviral Drug Product
- Table 147. Johnson & Johnson Revenue in HIV Antiretroviral Drug Business
- (2018-2023) & (US\$ Million)
- Table 148. Johnson & Johnson Recent Development
- Table 149. Biocon Limited Company Detail
- Table 150. Biocon Limited Business Overview
- Table 151. Biocon Limited HIV Antiretroviral Drug Product
- Table 152. Biocon Limited Revenue in HIV Antiretroviral Drug Business (2018-2023) & (US\$ Million)
- Table 153. Biocon Limited Recent Development
- Table 154. Affine Formulations Limited Company Detail
- Table 155. Affine Formulations Limited Business Overview
- Table 156. Affine Formulations Limited HIV Antiretroviral Drug Product
- Table 157. Affine Formulations Limited Revenue in HIV Antiretroviral Drug Business
- (2018-2023) & (US\$ Million)
- Table 158. Affine Formulations Limited Recent Development
- Table 159. IPCA Laboratories Company Detail
- Table 160. IPCA Laboratories Business Overview
- Table 161. IPCA Laboratories HIV Antiretroviral Drug Product
- Table 162. IPCA Laboratories Revenue in HIV Antiretroviral Drug Business (2018-2023)
- & (US\$ Million)
- Table 163. IPCA Laboratories Recent Development
- Table 164. Natco Pharma Company Detail
- Table 165. Natco Pharma Business Overview
- Table 166. Natco Pharma HIV Antiretroviral Drug Product
- Table 167. Natco Pharma Revenue in HIV Antiretroviral Drug Business (2018-2023) &
- (US\$ Million)
- Table 168. Natco Pharma Recent Development
- Table 169. Beacon Pharmaceuticals Company Detail
- Table 170. Beacon Pharmaceuticals Business Overview
- Table 171. Beacon Pharmaceuticals HIV Antiretroviral Drug Product
- Table 172. Beacon Pharmaceuticals Revenue in HIV Antiretroviral Drug Business
- (2018-2023) & (US\$ Million)
- Table 173. Beacon Pharmaceuticals Recent Development
- Table 174. Research Programs/Design for This Report
- Table 175. Key Data Information from Secondary Sources



Table 176. Key Data Information from Primary Sources



List Of Figures

LIST OF FIGURES

- Figure 1. Global HIV Antiretroviral Drug Market Size Comparison by Type (2023-2029) & (US\$ Million)
- Figure 2. Global HIV Antiretroviral Drug Market Share by Type: 2022 VS 2029
- Figure 3. Nucleoside Reverse Transcriptase Inhibitors Features
- Figure 4. Non-Nucleoside Reverse Transcriptase Inhibitors Features
- Figure 5. Protease Inhibitors Features
- Figure 6. Fusion Inhibitors Features
- Figure 7. Others Features
- Figure 8. Global HIV Antiretroviral Drug Market Size Comparison by Application (2023-2029) & (US\$ Million)
- Figure 9. Global HIV Antiretroviral Drug Market Share by Application: 2022 VS 2029
- Figure 10. Hospital Pharmacies Case Studies
- Figure 11. Retail Pharmacies Case Studies
- Figure 12. Online Pharmacies Case Studies
- Figure 13. HIV Antiretroviral Drug Report Years Considered
- Figure 14. Global HIV Antiretroviral Drug Market Size (US\$ Million), Year-over-Year: 2018-2029
- Figure 15. Global HIV Antiretroviral Drug Market Size, (US\$ Million), 2018 VS 2022 VS 2029
- Figure 16. Global HIV Antiretroviral Drug Market Share by Region: 2022 VS 2029
- Figure 17. Global HIV Antiretroviral Drug Market Share by Players in 2022
- Figure 18. Global Top HIV Antiretroviral Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HIV Antiretroviral Drug as of 2022)
- Figure 19. The Top 10 and 5 Players Market Share by HIV Antiretroviral Drug Revenue in 2022
- Figure 20. North America HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 21. North America HIV Antiretroviral Drug Market Share by Country (2018-2029)
- Figure 22. United States HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 23. Canada HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 24. Europe HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 25. Europe HIV Antiretroviral Drug Market Share by Country (2018-2029)



- Figure 26. Germany HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 27. France HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 28. U.K. HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 29. Italy HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 30. Russia HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 31. Nordic Countries HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 32. Asia-Pacific HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 33. Asia-Pacific HIV Antiretroviral Drug Market Share by Region (2018-2029)
- Figure 34. China HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 35. Japan HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 36. South Korea HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 37. Southeast Asia HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 38. India HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 39. Australia HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 40. Latin America HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 41. Latin America HIV Antiretroviral Drug Market Share by Country (2018-2029)
- Figure 42. Mexico HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 43. Brazil HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 44. Middle East & Africa HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 45. Middle East & Africa HIV Antiretroviral Drug Market Share by Country (2018-2029)
- Figure 46. Turkey HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US\$



Million)

Figure 47. Saudi Arabia HIV Antiretroviral Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 48. ViiV Healthcare(GlaxoSmithKline) Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)

Figure 49. Gilead Sciences Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)

Figure 50. AbbVie Inc. Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)

Figure 51. Merck & Co Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)

Figure 52. GSK Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)

Figure 53. Bristol-Myers Squibb Company Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)

Figure 54. Theratechnologies Inc. Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)

Figure 55. Roche Holding AG Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)

Figure 56. Teva Pharmaceuticals Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)

Figure 57. Pfizer Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)

Figure 58. Frontier Biotechnologies Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)

Figure 59. Shionogi Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)

Figure 60. Julphar Bangladesh Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)

Figure 61. Mylan Pharmaceuticals Inc. Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)

Figure 62. Genentech, Inc. Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)

Figure 63. Boehringer Ingelheim Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)

Figure 64. Cipla Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)

Figure 65. MSD Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)

Figure 66. Abbott Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)

Figure 67. Johnson & Johnson Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)



Figure 68. Biocon Limited Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)

Figure 69. Affine Formulations Limited Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)

Figure 70. IPCA Laboratories Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)

Figure 71. Natco Pharma Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)

Figure 72. Beacon Pharmaceuticals Revenue Growth Rate in HIV Antiretroviral Drug Business (2018-2023)

Figure 73. Bottom-up and Top-down Approaches for This Report

Figure 74. Data Triangulation

Figure 75. Key Executives Interviewed



I would like to order

Product name: Global HIV Antiretroviral Drug Market Research Report 2023

Product link: https://marketpublishers.com/r/G31180CEC21FEN.html

Price: US\$ 2,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G31180CEC21FEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970